Cytogenetic and molecular genetic changes in malignant mesothelioma

Our plain-English summary of Cytogenetic and molecular genetic changes in malignant mesothelioma, by M. Musti, E. Kettunen, S. Dragonieri, et al (Cancer Genetics and Cytogenetics, 2006).

The study

• Authors: M. Musti, E. Kettunen, S. Dragonieri, P. Lindholm, D. Cavone, G. Serio, S. Knuutila
• Journal: Cancer Genetics and Cytogenetics
• Published: 2006;170(1):9-15
• Type of article: Review
• Cited by: 74 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Abstract

Malignant mesothelioma (MM) results from the accumulation of a number of acquired genetic events, especially deletions, which lead to the inactivation of multiple onco-suppressor genes in a multistep cascade mechanism. Past asbestos exposure represents the major risk factor for MM, and the link between asbestos fibers and MM has been largely proved by several epidemiologic and experimental studies. Asbestos fibers induce DNA and chromosomal damage. Most MM cases have shown multiple chromosomal abnormalities. Chromosomal losses are more common than gains. The most common cytogenetic abnormality in MM is a deletion in 9p21, the locus of CDKN2A, a tumor suppressor gene (TSG). The deletion of CDKN2A is a negative prognostic factor in MM. Loss of TSG CDKN2A/p14(ARF) is also common in MM and mutations in NF2 occur in approximately half of the cases. Despite the ban on asbestos use in Western countries, the incidence of MM is increasing, and asbestos is still used in developing countries. This epidemiologic situation calls for further research. Ongoing studies are already applying high-throughput genomic profiling methods in MM. Genetic alterations observed in MM may be useful in differential diagnosis between lung cancer and MM, as diagnostic markers or therapeutic targets, and as indicators of premalignancy for primary prevention and health surveillance.

In plain English

This article was a review, not a new study. The authors gave an overview of genetic changes reported in malignant mesothelioma by earlier published research, and presented no new patients or data of their own. They described asbestos exposure as considered to contribute to this tumor in most patients, but did not analyze specific fiber types, jobs or doses. Summarizing earlier work, they reported that chromosome losses were more common than gains in mesothelioma. The most common abnormality was a deletion at a chromosome region called 9p21, which contains the CDKN2A gene, and deletion of CDKN2A was described as a negative prognostic factor. Mutations in the NF2 gene were reported in approximately half of cases, while TP53 mutations were not a prominent feature. One earlier study cited (Tiainen et al.) linked high asbestos fiber content in lung tissue with losses of chromosomes 1 and 4. The authors noted that genetic findings varied, with very limited overlap in prognostic gene lists between studies. They concluded that some chromosome changes appeared nonrandom and may be relevant events in how mesothelioma develops.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published cytogenetic and molecular genetic studies of malignant mesothelioma; no original data
• Who was studied: Earlier published studies of malignant mesothelioma tumors, cell lines and patients; the review does not state how many studies or patients were covered
• Exposure: Asbestos exposure, discussed in general terms as a contributor to mesothelioma in most patients; no fiber types, jobs or doses were analyzed
• Main results:
  • In the studies reviewed, chromosome losses in mesothelioma were more common than gains
  • In the studies reviewed, the most common cytogenetic abnormality in mesothelioma was deletion at 9p21, the location of the CDKN2A gene
  • Earlier work cited by the authors described deletion of CDKN2A as a negative prognostic factor in mesothelioma
  • Earlier work cited by the authors reported NF2 mutations in approximately half of mesothelioma cases
  • Earlier work cited by the authors found that TP53 mutations were not a very prominent feature in mesothelioma
  • A cited earlier study (Tiainen et al.) found a statistically significant correlation between high asbestos fiber content in lung tissue and partial or total losses of chromosomes 1 and 4
• The authors' conclusion: The authors concluded that some chromosomal aberrations appear to be nonrandom and may be relevant events in the development of mesothelioma
• Limitations the authors state:
  • The authors noted that the genetic changes reported seem somewhat variable, and that overlap in prognostic gene lists from different studies is very limited

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Malignant Mesothelioma, Asbestos Exposure, CDKN2A, Tumor Suppressor Gene, Differential Diagnosis, Lung Cancer.

Related studies

• Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma — A.A. Sandberg, J.A. Bridge (2001)
• Molecular and genetic changes in asbestos-related lung cancer — P. Nymark, H. Wikman, et al. (2008)
• Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies — J.S. Donington, D.J. Mew, et al. (1995)
• Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets — L.R. Motadi, N.L. Misso, et al. (2007)
• Pericardial synovial sarcoma, a potential for misdiagnosis: clinicopathologic and molecular cytogenetic analysis of three cases with literature review — Y. Cheng, W. Sheng, et al. (2012)
• Biologic, cytogenetic, and molecular factors in mesothelial proliferations — J. Hicks (2006)

Browse more research in Cancer Genetics and Cytogenetics, or return to medical research.